CAS No.: 2760889-65-2 Cat No.: BP-100171 Purity: ≥95%4.5
Pomalidomide-C6-I TFA is a high-purity E3 Ligase Ligand-Linker Conjugate designed for advanced PROTAC (Proteolysis Targeting Chimera) research and drug development. This compound features a pomalidomide-based cereblon (CRBN) ligand, a well-characterized E3 ubiquitin ligase recruiter, conjugated through a C6 alkyl linker and terminated with an iodo functional group, ideal for further chemical modifications. As a TFA (trifluoroacetate) salt, it ensures excellent solubility and stability in biological assays.
Pomalidomide-C6-I TFA plays a critical role in the design of PROTAC molecules by facilitating the recruitment of the CRBN E3 ligase and promoting target protein ubiquitination and subsequent degradation. This reagent is widely used in developing PROTACs targeting disease-relevant proteins such as kinases, transcription factors, and epigenetic regulators. Researchers utilize Pomalidomide-C6-I TFA to accelerate the identification and optimization of new small molecule degraders, expanding the frontiers of targeted protein degradation and next-generation therapeutics.
Structure of 2760889-65-2
Quality Assurance
Worldwide Delivery
24/7 Customer Support
Category
E3 Ligase Ligand-Linker Conjugate
Molecular Formula
C19H22IN3O4.C2HF3O2
Molecular Weight
597.33
Appearance
Solid
* For research and manufacturing use only. Not for human or clinical use.
Size
Price
Stock
Quantity
--
$--
In stock
Looking for different specifications? Click to request a custom quote!
Pomalidomide-C6-I TFA is a specialized E3 ligase ligand-linker conjugate designed to facilitate the development of targeted protein degradation tools, such as PROTACs (Proteolysis Targeting Chimeras). This compound is based on pomalidomide, a well-established cereblon (CRBN) E3 ligase ligand widely used in protein degradation research. The C6 linker with an iodine modification enables versatile conjugation strategies and efficient attachment of target-binding warheads.
Mechanism
Pomalidomide-C6-I TFA works by recruiting the CRBN E3 ubiquitin ligase complex through its pomalidomide moiety. When incorporated into a bifunctional PROTAC molecule, the C6 linker provides functional group flexibility for connecting to a ligand that binds the protein of interest. Upon administration, the PROTAC simultaneously binds the target protein and the E3 ligase, bringing them into close proximity and promoting ubiquitination of the target. This ubiquitination marks the target protein for proteasomal degradation, effectively eliminating it from the cell.
Applications
Pomalidomide-C6-I TFA is widely used in the synthesis of PROTACs and other targeted protein degradation tools. It enables researchers to construct custom chimeric molecules for selectively degrading disease-related proteins in oncology, neurodegenerative disorders, and immunological diseases. This conjugate is also valuable for chemical biology studies, drug discovery programs, and understanding protein homeostasis mechanisms. Its versatility and efficiency make it a preferred choice for developing next-generation therapeutics that harness the power of targeted protein degradation.
• Iodo-functionalized C6 linker enables versatile conjugation to a broad range of warhead molecules, supporting flexible PROTAC design.
• Pomalidomide moiety ensures high affinity binding to CRBN E3 ligase, optimizing targeted protein degradation in cell-based assays.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
CAS No.: 2760889-65-2
Purity: ≥95%
